Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival

References

• Tollefson MK, Karnes RJ, Rangel LJ, et al. The impact of clinical stage on prostate cancer survival following radical prostatectomy. J Urol. 2013;189:1707–1712.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66:243–250.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. JCO. 2009;27:4300–4305.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32–39.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. JCO. 2007;25:2035–2041.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Lohm G, Bottke D, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome–results of a retrospective study. Int J Radiat Oncol Biol Phys. 2009;73:1009–1016.
   PubMed Web of Science ®Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642.
   PubMed Web of Science ®Google Scholar
• Mir MC, Li J, Klink JC, et al. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. 2014;66:204–210.
   PubMed Web of Science ®Google Scholar
• Briganti A, Wiegel T, Joniau S, et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol. 2012;62:472–487.
   PubMed Web of Science ®Google Scholar
• Stish BJ, Pisansky TM, Harmsen WS, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol. 2016;34:3864--3871.
   PubMed Web of Science ®Google Scholar
• Bartkowiak D, Bottke D, Thamm R, et al. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Radiother Oncol. 2016;118:131–135.
   PubMed Web of Science ®Google Scholar
• Geinitz H, Riegel MG, Thamm R, et al. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82:1930–1937.
   PubMed Web of Science ®Google Scholar
• Jackson WC, Johnson SB, Foster B, et al. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol. 2014;4:99–107.
   PubMedGoogle Scholar
• Bottke D, Bartkowiak D, Schrader M, et al. Radiotherapy after radical prostatectomy: immediate or early delayed? Strahlenther Onkol. 2012;188:1096–1101.
   PubMed Web of Science ®Google Scholar
• Abugharib A, Jackson WC, Tumati V, et al. 'Very Early' salvage radiotherapy improves distant metastasis-free survival. J Urol. 2016;197:662–668.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–2027.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–962.
   PubMed Web of Science ®Google Scholar
• King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys. 2008;71:346–350.
   PubMed Web of Science ®Google Scholar
• Ost P, De Troyer B, Fonteyne V, et al. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80:1316–1322.
   PubMed Web of Science ®Google Scholar
• Goenka A, Magsanoc JM, Pei X, et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol. 2011;60:1142–1148.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Hayoz S, Bernhard J, et al. Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. JCO. 2015;33:4158–4166.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative Intent. Eur Urol. 2017;71:618–629.
   PubMed Web of Science ®Google Scholar
• Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34:3648--3654.
   PubMed Web of Science ®Google Scholar
• Fossati N, Karnes RJ, Cozzarini C, et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol. 2016;69:728–733.
   PubMed Web of Science ®Google Scholar
• Ervandian M, Hoyer M, Petersen SE, et al. Salvage radiation therapy following radical prostatectomy. A national Danish study. Acta Oncol. 2016;55:598–603.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Sutter ME, Dorey F, et al. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61:365–369.
   PubMed Web of Science ®Google Scholar
• Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17:747–756.
   PubMed Web of Science ®Google Scholar
• Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017;376:417–428.
   PubMed Web of Science ®Google Scholar